Literature DB >> 31554634

CAR T cell viability release testing and clinical outcomes: is there a lower limit?

Elise A Chong1, Bruce L Levine1, Stephan A Grupp2, Megan M Davis1, Don L Siegel1, Shannon L Maude2, Whitney L Gladney1, Noelle V Frey1, David L Porter1, Wei-Ting Hwang1, Emeline R Chong1, Carl H June1, Stephen J Schuster1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31554634      PMCID： PMC6872962          DOI： 10.1182/blood.2019002258

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  4 in total

1.  Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

Authors:  Stephen J Schuster; Michael R Bishop; Constantine S Tam; Edmund K Waller; Peter Borchmann; Joseph P McGuirk; Ulrich Jäger; Samantha Jaglowski; Charalambos Andreadis; Jason R Westin; Isabelle Fleury; Veronika Bachanova; S Ronan Foley; P Joy Ho; Stephan Mielke; John M Magenau; Harald Holte; Serafino Pantano; Lida B Pacaud; Rakesh Awasthi; Jufen Chu; Özlem Anak; Gilles Salles; Richard T Maziarz
Journal:  N Engl J Med       Date:  2018-12-01       Impact factor: 91.245

2.  Chimeric antigen receptor T cells for sustained remissions in leukemia.

Authors:  Shannon L Maude; Noelle Frey; Pamela A Shaw; Richard Aplenc; David M Barrett; Nancy J Bunin; Anne Chew; Vanessa E Gonzalez; Zhaohui Zheng; Simon F Lacey; Yolanda D Mahnke; Jan J Melenhorst; Susan R Rheingold; Angela Shen; David T Teachey; Bruce L Levine; Carl H June; David L Porter; Stephan A Grupp
Journal:  N Engl J Med       Date:  2014-10-16       Impact factor: 91.245

3.  Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas.

Authors:  Stephen J Schuster; Jakub Svoboda; Elise A Chong; Sunita D Nasta; Anthony R Mato; Özlem Anak; Jennifer L Brogdon; Iulian Pruteanu-Malinici; Vijay Bhoj; Daniel Landsburg; Mariusz Wasik; Bruce L Levine; Simon F Lacey; Jan J Melenhorst; David L Porter; Carl H June
Journal:  N Engl J Med       Date:  2017-12-10       Impact factor: 91.245

4.  Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.

Authors:  Shannon L Maude; Theodore W Laetsch; Jochen Buechner; Susana Rives; Michael Boyer; Henrique Bittencourt; Peter Bader; Michael R Verneris; Heather E Stefanski; Gary D Myers; Muna Qayed; Barbara De Moerloose; Hidefumi Hiramatsu; Krysta Schlis; Kara L Davis; Paul L Martin; Eneida R Nemecek; Gregory A Yanik; Christina Peters; Andre Baruchel; Nicolas Boissel; Francoise Mechinaud; Adriana Balduzzi; Joerg Krueger; Carl H June; Bruce L Levine; Patricia Wood; Tetiana Taran; Mimi Leung; Karen T Mueller; Yiyun Zhang; Kapildeb Sen; David Lebwohl; Michael A Pulsipher; Stephan A Grupp
Journal:  N Engl J Med       Date:  2018-02-01       Impact factor: 91.245
  4 in total
  6 in total

1.  Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B Cell Lymphomas.

Authors:  Peter A Riedell; Wei-Ting Hwang; Loretta J Nastoupil; Martina Pennisi; Joseph P McGuirk; Richard T Maziarz; Veronika Bachanova; Olalekan O Oluwole; Jamie Brower; Oscar A Flores; Nausheen Ahmed; Levanto Schachter; Kharmen Bharucha; Bhagirathbhai R Dholaria; Stephen J Schuster; Miguel-Angel Perales; Michael R Bishop; David L Porter
Journal:  Transplant Cell Ther       Date:  2022-07-16

Review 2.  Role of CD19 Chimeric Antigen Receptor T Cells in Second-Line Large B Cell Lymphoma: Lessons from Phase 3 Trials. An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.

Authors:  Miguel-Angel Perales; Larry D Anderson; Tania Jain; Saad S Kenderian; Olalekan O Oluwole; Gunjan L Shah; Jakub Svoboda; Mehdi Hamadani
Journal:  Transplant Cell Ther       Date:  2022-06-26

Review 3.  Improving CAR T cell therapy by optimizing critical quality attributes.

Authors:  Opal L Reddy; David F Stroncek; Sandhya R Panch
Journal:  Semin Hematol       Date:  2020-07-27       Impact factor: 3.851

Review 4.  Chimeric Antigen Receptor T-Cell Therapy in Paediatric B-Cell Precursor Acute Lymphoblastic Leukaemia: Curative Treatment Option or Bridge to Transplant?

Authors:  Jochen Buechner; Ignazio Caruana; Annette Künkele; Susana Rives; Kim Vettenranta; Peter Bader; Christina Peters; André Baruchel; Friso G Calkoen
Journal:  Front Pediatr       Date:  2022-01-25       Impact factor: 3.418

5.  In Vivo Cellular Expansion of Lisocabtagene Maraleucel and Association With Efficacy and Safety in Relapsed/Refractory Large B-Cell Lymphoma.

Authors:  Ken Ogasawara; James Lymp; Timothy Mack; Justine Dell'Aringa; Chang-Pin Huang; Jeff Smith; Leanne Peiser; Ana Kostic
Journal:  Clin Pharmacol Ther       Date:  2022-03-20       Impact factor: 6.903

6.  Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma.

Authors:  Marcelo C Pasquini; Zhen-Huan Hu; Kevin Curran; Theodore Laetsch; Frederick Locke; Rayne Rouce; Michael A Pulsipher; Christine L Phillips; Amy Keating; Matthew J Frigault; Dana Salzberg; Samantha Jaglowski; Joshua P Sasine; Joseph Rosenthal; Monalisa Ghosh; Daniel Landsburg; Steven Margossian; Paul L Martin; Manali K Kamdar; Peiman Hematti; Sarah Nikiforow; Cameron Turtle; Miguel-Angel Perales; Patricia Steinert; Mary M Horowitz; Amy Moskop; Lida Pacaud; Lan Yi; Raghav Chawla; Eric Bleickardt; Stephan Grupp
Journal:  Blood Adv       Date:  2020-11-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.